Samsung Biologics Acquires GSK’s Manufacturing Facility in Maryland, US
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
Samsung Biologics
Samsung Biologics Signs Manufacturing Deal with European Pharmaceutical Company
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
The CDMO/CMO Report
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
Samsung Biologics and Pfizer in Biosimilars Pact
South Korean CDMO Samsung Biologics has entered into a long-term manufacturing partnership with major drugmaker Pfizer.
Pharma CEOs Take Action on Climate Change
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
Samsung Biologics in $81 Million Deal with Novartis
In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.
Ramping Up Biomanufacturing Capacity
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.
Samsung Biologics to Take Control of Bioepis JV
Samsung Biologics has agreed to buy out partner Biogen’s share of their Samsung Bioepis joint venture for up to $2.3 billion. The South Korean group said the deal will accelerate growth in biosimilars and novel therapeutics R&D.
